Recurrent Breast Carcinoma (DBCOND0030216)

Identifiers

Synonyms

Breast carcinoma recurrent / Carcinoma breast recurrent / Recurrent Carcinoma, Breast / Breast cancer recurrent / Breast cancer NOS recurrent / Breast carcinoma NOS recurrent

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Megestrol acetate	A progestin that is administered orally to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat certain types of malignancy.	Progesterone receptortarget Glucocorticoid receptortarget ATP-dependent translocase ABCB1transporter Cytochrome P450 3A4enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04521764	A Vaccine (MV-s-NAP) for the Treatment of Patients with Invasive Metastatic Breast Cancer	Measles virus vaccine live attenuated	treatment	1	recruiting
NCT01434303	Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only	Entinostat Lapatinib Trastuzumab	treatment	1	completed
NCT02370264	Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer	No drug interventions	supportive_care	Not Available	terminated
NCT01922921	Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy	Pertuzumab Trastuzumab	treatment	1 / 2	completed
NCT04297384	Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice	No drug interventions	health_services_research	Not Available	completed
NCT00450879	Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery	Pazopanib	treatment	1	terminated
NCT01638533	Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction	Romidepsin	treatment	1	active_not_recruiting
NCT01263145	MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer	Paclitaxel	treatment	1	completed
NCT02595905	Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases	Chloride ion Cisplatin Platinum Veliparib	treatment	2	active_not_recruiting
NCT03939897	Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer	Abemaciclib Copanlisib Fulvestrant	treatment	1 / 2	active_not_recruiting
NCT00376688	Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer	Menthol Sirolimus Temsirolimus	treatment	2	completed
NCT03971409	Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer	Avelumab Binimetinib Doxorubicin Ivuxolimab Sacituzumab govitecan Utomilumab	treatment	2	recruiting
NCT01351909	Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer	Cyclophosphamide Veliparib	treatment	1	active_not_recruiting
NCT00054132	Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer	Bevacizumab Erlotinib	treatment	2	completed
NCT00601900	Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer	Bevacizumab Letrozole Tamoxifen	treatment	3	active_not_recruiting
NCT02672475	Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer	Galunisertib Paclitaxel	treatment	1	completed
NCT02824575	Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer	Eribulin Paclitaxel Rebastinib	treatment	1	terminated
NCT02208375	mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian	Capivasertib Olaparib Vistusertib	treatment	1 / 2	active_not_recruiting
NCT03725436	ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors	Paclitaxel Sulanemadlin	treatment	1	active_not_recruiting
NCT00892736	Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy	Veliparib	treatment	1	completed
NCT04418219	Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer	Cyclophosphamide Pembrolizumab	treatment	1 / 2	withdrawn
NCT02646319	Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations	Albumin human Sirolimus	treatment	0	completed
NCT01606241	Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Benzalkonium Cyclophosphamide Folic acid	treatment	1	completed
NCT03432741	Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer	Belinostat Carfilzomib Copanlisib Daratumumab Fludeoxyglucose (18F) Fluorine F-18 Gemcitabine Nivolumab Obinutuzumab Pembrolizumab Rituximab Romidepsin Trastuzumab	treatment	1	suspended
NCT01131234	Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	Cediranib RG-4733	treatment	1	completed
NCT01276496	Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery	Cilengitide Paclitaxel	treatment	1	completed
NCT01816035	Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery	Trastuzumab emtansine	treatment	1	completed
NCT02650635	TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors	Cyclophosphamide Filgrastim Motolimod Pegfilgrastim	treatment	1	terminated
NCT02996825	Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer	Gemcitabine Mirvetuximab Mirvetuximab soravtansine	treatment	1	completed
NCT01145430	Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer	Doxorubicin Tetracycline Veliparib	treatment	1	completed
NCT03364348	4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer	Trastuzumab Trastuzumab emtansine Utomilumab	treatment	1	completed
NCT01277757	Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer	MK-2206	treatment	2	completed
NCT06217874	Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT01522820	Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors	Cancer/testis antigen 1 Rasdegafusp alfa Sirolimus	treatment	1	completed
NCT02115282	Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic	Entinostat Exemestane Goserelin	treatment	3	active_not_recruiting
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	ABSK-091 Adavosertib Afatinib Binimetinib Capivasertib Copanlisib Crizotinib Dabrafenib Dasatinib Defactinib Erdafitinib GSK-2636771 Ipatasertib Larotrectinib Methane Nivolumab Osimertinib Palbociclib Pertuzumab Relatlimab Sapanisertib Sulfate ion Sunitinib Taselisib Trametinib Trastuzumab Trastuzumab emtansine Tyrosine Ulixertinib Vismodegib	screening	2	active_not_recruiting
NCT00699491	Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer	Cixutumumab Menthol Sirolimus Temsirolimus	treatment	1 / 2	completed
NCT00785291	Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer	Albumin human Bevacizumab Ixabepilone Paclitaxel Patupilone	treatment	3	completed
NCT03644589	Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer	Cisplatin Pembrolizumab	treatment	2	withdrawn
NCT01908101	Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer	Eribulin	treatment	2	completed
NCT01463072	Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer	Albumin human Paclitaxel	treatment	2	active_not_recruiting
NCT02658812	Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery	Talimogene laherparepvec	treatment	2	terminated
NCT02774681	Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis	Palbociclib Trastuzumab	treatment	2	terminated
NCT03737695	Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer	No drug interventions	Not Available	Not Available	suspended
NCT03987555	Paclitaxel Therapeutic Drug Monitoring in Cancer Patients	No drug interventions	Not Available	Not Available	recruiting
NCT00390455	Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive	Fulvestrant Lapatinib	treatment	3	completed
NCT00100750	Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer	Gemcitabine Tipifarnib	treatment	1 / 2	completed
NCT01776008	Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer	Anastrozole Goserelin	treatment	2	terminated
NCT00998738	Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer	Calcium Calcium gluconate Ixabepilone Magnesium sulfate	supportive_care	3	terminated
NCT02152943	Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients	Everolimus Letrozole Trastuzumab	treatment	1	completed
NCT00066690	Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer	Exemestane Gonadorelin Tamoxifen Triptorelin Tryptophan	treatment	3	active_not_recruiting
NCT01071564	RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery	RG-4733 Vismodegib	treatment	1	terminated
NCT03281902	Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT02415387	Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer	Typhoid vaccine	basic_science	0	completed
NCT02311933	Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer	Tamoxifen	treatment	2	active_not_recruiting
NCT02157051	Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer	No drug interventions	treatment	1	active_not_recruiting
NCT01275677	Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer	Cyclophosphamide Daunorubicin Docetaxel Doxorubicin Paclitaxel Trastuzumab	treatment	3	active_not_recruiting
NCT00684983	Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer	Capecitabine Cixutumumab Lapatinib	treatment	2	completed
NCT03418961	S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer	Carvedilol	supportive_care	3	recruiting
NCT01697293	PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer	Cyclophosphamide Doxorubicin Paclitaxel Triciribine Triciribine phosphate	treatment	1 / 2	terminated
NCT02898207	Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer	Olaparib Onalespib	treatment	1	completed
NCT01149356	RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer	Exemestane Goserelin RG-4733	treatment	1	terminated
NCT01349959	Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer	Azacitidine Entinostat	treatment	2	active_not_recruiting
NCT00520975	Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU	Bevacizumab Carboplatin Paclitaxel Trastuzumab	treatment	3	terminated
NCT01624441	Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer	Dinaciclib Epirubicin	treatment	1	completed
NCT03213041	Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer	Carboplatin Pembrolizumab	treatment	2	recruiting
NCT01552434	Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	Bevacizumab Cetuximab Menthol Sirolimus Temsirolimus Valproic acid	treatment	1	active_not_recruiting
NCT02206334	Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer	No drug interventions	treatment	1	completed
NCT01964924	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer	Trametinib Uprosertib	treatment	2	completed
NCT01281163	Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer	Lapatinib	treatment	1	terminated
NCT01575522	Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer	Tivantinib	treatment	2	completed
NCT03941730	Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer	Estradiol	treatment	2	active_not_recruiting
NCT03044730	Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery	Capecitabine Pembrolizumab	treatment	2	unknown_status
NCT02627430	Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer	Onalespib Talazoparib	treatment	1	withdrawn
NCT00118157	Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen	Lapatinib Tamoxifen	treatment	2	completed
NCT01251874	Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer	Carboplatin Veliparib	treatment	1	completed
NCT01344031	MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer	Anastrozole Fulvestrant	treatment	1	completed
NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	Albumin human Alectinib Alpelisib Anastrozole Atezolizumab Bevacizumab Capecitabine Carboplatin Cobimetinib Entrectinib Eribulin Fulvestrant Hyaluronidase (human recombinant) Irinotecan Letrozole Niraparib Olaparib Paclitaxel Palbociclib Pertuzumab Trastuzumab Trastuzumab emtansine Vemurafenib Vinorelbine Vismodegib	treatment	0	withdrawn
NCT02149173	F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy	Fludeoxyglucose (18F) Fluorine F-18 Fluoroestradiol F-18	diagnostic	Not Available	terminated
NCT02536794	MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer	Durvalumab Tremelimumab	treatment	2	completed
NCT03207529	Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer	Alpelisib Enzalutamide	treatment	1	completed
NCT02219789	Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery	Alisertib Fulvestrant	treatment	1	completed
NCT04529044	177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer	Lutetium Lu 177 dotatate	treatment	2	unknown_status
NCT03554044	T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer	Anastrozole Carboplatin Exemestane Fulvestrant Gemcitabine Letrozole Paclitaxel Talimogene laherparepvec Tamoxifen	treatment	1	active_not_recruiting
NCT06324240	Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer	Ipilimumab Pembrolizumab	treatment	1	not_yet_recruiting
NCT03955640	Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences	Olaparib	treatment	1	unknown_status
NCT04022772	Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer	No drug interventions	supportive_care	Not Available	completed
NCT01622868	Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer	Lapatinib	treatment	2	completed
NCT01327781	Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer	No drug interventions	treatment	1	active_not_recruiting
NCT04052555	Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer	Berzosertib	treatment	1	active_not_recruiting
NCT01281150	Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors	Carboplatin Paclitaxel Veliparib	treatment	1	completed